首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1390756

抗體藥物偶聯物市場：2023-2028 年全球產業趨勢、佔有率、規模、成長、機會與預測

Antibody Drug Conjugates Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

出版日期: 2023年11月24日 | 出版商:

IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

概要

2022年全球抗體藥物偶聯物市場規模達63億美元。展望未來， IMARC Group預計到2028年市場規模將達到224億美元，2022-2028年複合年成長率（CAGR）為23.54%。

抗體藥物偶聯物 (ADC) 是包含腫瘤靶向抗體的高效生物藥物，這些抗體透過化學方式附著在細胞毒性效應分子上。它們透過可生物分解的連接體將細胞毒性抗癌劑連接到單株抗體(mAb)，並允許健康組織和患病組織之間敏感的分叉，從而將細胞毒性抗癌劑傳遞給受影響的細胞。與標準化療生物活性化合物相比，它們有助於提高 mAb 的細胞殺傷潛力、增強藥物耐受性並限制系統暴露。目前，它們透過靜脈注射進入血流，以避免單株抗體被胃酸和蛋白質水解酶分解。

抗體藥物偶聯物市場趨勢：

由於久坐的生活方式以及經常吸煙和飲酒的人數不斷增加，世界各地癌症的盛行率增加。這與對具有成本效益和成功的癌症治療的需求不斷成長相結合，是推動市場成長的關鍵因素之一。除此之外，現有的連接器經常非特異性地釋放有效負載並導致脫靶毒性，這嚴重影響了ADC的開發。因此，領先企業不斷資助他們的研發 (R&D) 項目，以最佳化現有的化學觸發器並開發新型化學觸發劑以產生高度選擇性的連接體。他們還提出了新穎的接頭-抗體附件，以生產穩定且同質的 ADC，以及額外的接頭-有效負載附件，以允許擴展有效負載。此外，他們還致力於改善吸收、分佈、代謝和排泄，這創造了良好的市場前景。其他主要因素，包括顯著改善醫療基礎設施、提高對可用於癌症治療的療法的認知以及引入可裂解連接器技術，預計將推動市場成長。

本報告回答的關鍵問題：

迄今為止，全球抗體藥物偶聯物市場表現如何，未來幾年將如何表現？
COVID-19 對全球抗體藥物偶聯物市場有何影響？
主要區域市場有哪些？
基於組件的市場區隔是什麼？
基於目標的市場區隔是什麼？
基於應用程式的市場區隔是什麼？
基於最終用戶的市場區隔是什麼？
產業價值鏈的各個階段是什麼？
該行業的關鍵促進因素和挑戰是什麼？
全球抗體藥物偶聯物市場的結構如何？誰是主要參與者？
產業競爭程度如何？

北美洲
- 美國
  - 市場走向
  - 市場預測
- 加拿大
  - 市場走向
  - 市場預測
亞太
- 中國
  - 市場走向
  - 市場預測
- 日本
  - 市場走向
  - 市場預測
- 印度
  - 市場走向
  - 市場預測
- 韓國
  - 市場走向
  - 市場預測
- 澳洲
  - 市場走向
  - 市場預測
- 印尼
  - 市場走向
  - 市場預測
- 其他
  - 市場走向
  - 市場預測
歐洲
- 德國
  - 市場走向
  - 市場預測
- 法國
  - 市場走向
  - 市場預測
- 英國
  - 市場走向
  - 市場預測
- 義大利
  - 市場走向
  - 市場預測
- 西班牙
  - 市場走向
  - 市場預測
- 俄羅斯
  - 市場走向
  - 市場預測
- 其他
  - 市場走向
  - 市場預測
拉丁美洲
- 巴西
  - 市場走向
  - 市場預測
- 墨西哥
  - 市場走向
  - 市場預測
- 其他
  - 市場走向
  - 市場預測
中東和非洲
- 市場走向
- 按國家/地區分類的市場細分
- 市場預測

第 11 章：SWOT 分析

概述
優勢
弱點
機會
威脅

第 12 章：價值鏈分析

第 13 章：波特五力分析

概述
買家的議價能力
供應商的議價能力
競爭程度
新進入者的威脅
替代品的威脅

第 14 章：價格分析

第15章：競爭格局

市場結構
關鍵參與者
關鍵參與者簡介
- ADC Therapeutics SA
- Astellas Pharma Inc.
- AstraZeneca plc
- Celldex Therapeutics Inc.
- F. Hoffmann-La Roche AG
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- ImmunoGen Inc
- Pfizer Inc.
- Sanofi SA
- Seagen Inc.
- Sorrento Therapeutics Inc.
- Takeda Pharmaceutical Company Ltd.

簡介目錄圖表

Product Code: SR112023A4604

Abstract

The global antibody drug conjugates market size reached US$ 6.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 22.4 Billion by 2028, exhibiting a growth rate (CAGR) of 23.54% during 2022-2028.

Antibody drug conjugates (ADCs) are highly potent biological drugs comprising tumor-targeting antibodies, which are chemically attached to a cytotoxic effector molecule. They deliver cytotoxic anticancer agents to affected cells by connecting them to monoclonal antibodies (mAb) through biodegradable linkers and allowing sensitive bifurcation between healthy and diseased tissues. They assist in increasing the cell-killing potential of mAb, enhancing drug tolerability, and limiting systematic exposure compared to standard chemotherapy bioactive compounds. At present, they are administered intravenously into the bloodstream to avoid gastric acid and proteolytic enzyme degradation of the mAb.

Antibody Drug Conjugates Market Trends:

Due to sedentary lifestyles and the rising number of individuals who smoke and drink regularly, there is an increase in the prevalence of cancer around the world. This, in confluence with the escalating demand for cost-effective and successful cancer treatments, represents one of the key factors bolstering the growth of the market. Apart from this, the existing linkers often release payloads nonspecifically and lead to off-target toxicity, which severely affects the development of ADCs. As a result, leading players are continuously funding their research and development (R&D) projects to optimize the existing chemical triggers and develop novel chemical triggers to generate highly selective linkers. They are also coming up with novel linker-antibody attachments to produce stable and homogenous ADCs and additional linker-payload attachments to allow the expansion of payloads. Moreover, they are focusing on improving the absorption, distribution, metabolism, and excretion, which is creating a favorable market outlook. Other major factors, including considerably improving healthcare infrastructure, increasing awareness about therapies available for cancer treatments, and the introduction of cleavable linker technology, are anticipated to propel the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global antibody drug conjugates market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on component, target, application and end user.

Breakup by Component:

Monoclonal Antibodies

Linker

Cytotoxic Agent

Others

Breakup by Target:

Antibody-Protein Toxin Conjugates

Antibody-Chelated Radionuclide Conjugates

Antibody-Small-Molecule Drug Conjugates

Antibody-Enzyme Conjugates

Breakup by Application:

Lymphoma

Ovarian Cancer

Lung Cancer

Breast Cancer

Brain Tumor

Others

Breakup by End User:

Hospitals

Specialized Cancer Centers

Academic Research Institutes

Biotechnology Companies

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca plc, Celldex Therapeutics Inc., F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline Plc, ImmunoGen Inc, Pfizer Inc., Sanofi S.A., Seagen Inc., Sorrento Therapeutics Inc. and Takeda Pharmaceutical Company Ltd.

Key Questions Answered in This Report:

How has the global antibody drug conjugates market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global antibody drug conjugates market?
What are the key regional markets?
What is the breakup of the market based on the component?
What is the breakup of the market based on the target?
What is the breakup of the market based on the application?
What is the breakup of the market based on the end user?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global antibody drug conjugates market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Antibody Drug Conjugates Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Component

6.1 Monoclonal Antibodies
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Linker
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Cytotoxic Agent
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast

7 Market Breakup by Target

7.1 Antibody-Protein Toxin Conjugates
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Antibody-Chelated Radionuclide Conjugates
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Antibody-Small-Molecule Drug Conjugates
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Antibody-Enzyme Conjugates
- 7.4.1 Market Trends
- 7.4.2 Market Forecast

8 Market Breakup by Application

8.1 Lymphoma
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Ovarian Cancer
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Lung Cancer
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Breast Cancer
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
8.5 Brain Tumor
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
8.6 Others
- 8.6.1 Market Trends
- 8.6.2 Market Forecast

9 Market Breakup by End User

9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Specialized Cancer Centers
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Academic Research Institutes
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
9.4 Biotechnology Companies
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
9.5 Others
- 9.5.1 Market Trends
- 9.5.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia-Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 ADC Therapeutics SA
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
- 15.3.2 Astellas Pharma Inc.
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 Financials
  - 15.3.2.4 SWOT Analysis
- 15.3.3 AstraZeneca plc
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
  - 15.3.3.4 SWOT Analysis
- 15.3.4 Celldex Therapeutics Inc.
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 F. Hoffmann-La Roche AG
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
- 15.3.6 Gilead Sciences Inc.
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
  - 15.3.6.4 SWOT Analysis
- 15.3.7 GlaxoSmithKline Plc
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
  - 15.3.7.4 SWOT Analysis
- 15.3.8 ImmunoGen Inc
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
  - 15.3.8.4 SWOT Analysis
- 15.3.9 Pfizer Inc.
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 Sanofi S.A.
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 Financials
  - 15.3.10.4 SWOT Analysis
- 15.3.11 Seagen Inc.
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
  - 15.3.11.3 Financials
  - 15.3.11.4 SWOT Analysis
- 15.3.12 Sorrento Therapeutics Inc.
  - 15.3.12.1 Company Overview
  - 15.3.12.2 Product Portfolio
  - 15.3.12.3 Financials
- 15.3.13 Takeda Pharmaceutical Company Ltd.
  - 15.3.13.1 Company Overview
  - 15.3.13.2 Product Portfolio
  - 15.3.13.3 Financials
  - 15.3.13.4 SWOT Analysis

簡介目錄圖表

List of Figures

Figure 1: Global: Antibody Drug Conjugates Market: Major Drivers and Challenges
Figure 2: Global: Antibody Drug Conjugates Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Antibody Drug Conjugates Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 4: Global: Antibody Drug Conjugates Market: Breakup by Component (in %), 2022
Figure 5: Global: Antibody Drug Conjugates Market: Breakup by Target (in %), 2022
Figure 6: Global: Antibody Drug Conjugates Market: Breakup by Application (in %), 2022
Figure 7: Global: Antibody Drug Conjugates Market: Breakup by End User (in %), 2022
Figure 8: Global: Antibody Drug Conjugates Market: Breakup by Region (in %), 2022
Figure 9: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 10: Global: Antibody Drug Conjugates (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 11: Global: Antibody Drug Conjugates (Linker) Market: Sales Value (in Million US$), 2017 & 2022
Figure 12: Global: Antibody Drug Conjugates (Linker) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 13: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market: Sales Value (in Million US$), 2017 & 2022
Figure 14: Global: Antibody Drug Conjugates (Cytotoxic Agent) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 15: Global: Antibody Drug Conjugates (Other Components) Market: Sales Value (in Million US$), 2017 & 2022
Figure 16: Global: Antibody Drug Conjugates (Other Components) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 17: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market: Sales Value (in Million US$), 2017 & 2022
Figure 18: Global: Antibody Drug Conjugates (Antibody-Protein Toxin Conjugates) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 19: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market: Sales Value (in Million US$), 2017 & 2022
Figure 20: Global: Antibody Drug Conjugates (Antibody-Chelated Radionuclide Conjugates) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 21: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market: Sales Value (in Million US$), 2017 & 2022
Figure 22: Global: Antibody Drug Conjugates (Antibody-Small-Molecule Drug Conjugates) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 23: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market: Sales Value (in Million US$), 2017 & 2022
Figure 24: Global: Antibody Drug Conjugates (Antibody-Enzyme Conjugates) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 25: Global: Antibody Drug Conjugates (Lymphoma) Market: Sales Value (in Million US$), 2017 & 2022
Figure 26: Global: Antibody Drug Conjugates (Lymphoma) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 27: Global: Antibody Drug Conjugates (Ovarian Cancer) Market: Sales Value (in Million US$), 2017 & 2022
Figure 28: Global: Antibody Drug Conjugates (Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 29: Global: Antibody Drug Conjugates (Lung Cancer) Market: Sales Value (in Million US$), 2017 & 2022
Figure 30: Global: Antibody Drug Conjugates (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 31: Global: Antibody Drug Conjugates (Breast Cancer) Market: Sales Value (in Million US$), 2017 & 2022
Figure 32: Global: Antibody Drug Conjugates (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 33: Global: Antibody Drug Conjugates (Brain Tumor) Market: Sales Value (in Million US$), 2017 & 2022
Figure 34: Global: Antibody Drug Conjugates (Brain Tumor) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 35: Global: Antibody Drug Conjugates (Other Applications) Market: Sales Value (in Million US$), 2017 & 2022
Figure 36: Global: Antibody Drug Conjugates (Other Applications) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 37: Global: Antibody Drug Conjugates (Hospitals) Market: Sales Value (in Million US$), 2017 & 2022
Figure 38: Global: Antibody Drug Conjugates (Hospitals) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 39: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market: Sales Value (in Million US$), 2017 & 2022
Figure 40: Global: Antibody Drug Conjugates (Specialized Cancer Centers) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 41: Global: Antibody Drug Conjugates (Academic Research Institutes) Market: Sales Value (in Million US$), 2017 & 2022
Figure 42: Global: Antibody Drug Conjugates (Academic Research Institutes) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 43: Global: Antibody Drug Conjugates (Biotechnology Companies) Market: Sales Value (in Million US$), 2017 & 2022
Figure 44: Global: Antibody Drug Conjugates (Biotechnology Companies) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 45: Global: Antibody Drug Conjugates (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
Figure 46: Global: Antibody Drug Conjugates (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 47: North America: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 48: North America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 49: United States: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 50: United States: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 51: Canada: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 52: Canada: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 53: Asia-Pacific: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 54: Asia-Pacific: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 55: China: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 56: China: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 57: Japan: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 58: Japan: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 59: India: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 60: India: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 61: South Korea: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 62: South Korea: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 63: Australia: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 64: Australia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 65: Indonesia: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 66: Indonesia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 67: Others: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 68: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 69: Europe: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 70: Europe: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 71: Germany: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 72: Germany: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 73: France: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 74: France: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 75: United Kingdom: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 76: United Kingdom: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 77: Italy: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 78: Italy: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 79: Spain: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 80: Spain: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 81: Russia: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 82: Russia: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 83: Others: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 84: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 85: Latin America: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 86: Latin America: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 87: Brazil: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 88: Brazil: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 89: Mexico: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 90: Mexico: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 91: Others: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 92: Others: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 93: Middle East and Africa: Antibody Drug Conjugates Market: Sales Value (in Million US$), 2017 & 2022
Figure 94: Middle East and Africa: Antibody Drug Conjugates Market: Breakup by Country (in %), 2022
Figure 95: Middle East and Africa: Antibody Drug Conjugates Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 96: Global: Antibody Drug Conjugates Industry: SWOT Analysis
Figure 97: Global: Antibody Drug Conjugates Industry: Value Chain Analysis
Figure 98: Global: Antibody Drug Conjugates Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Antibody Drug Conjugates Market: Key Industry Highlights, 2022 and 2028
Table 2: Global: Antibody Drug Conjugates Market Forecast: Breakup by Component (in Million US$), 2023-2028
Table 3: Global: Antibody Drug Conjugates Market Forecast: Breakup by Target (in Million US$), 2023-2028
Table 4: Global: Antibody Drug Conjugates Market Forecast: Breakup by Application (in Million US$), 2023-2028
Table 5: Global: Antibody Drug Conjugates Market Forecast: Breakup by End User (in Million US$), 2023-2028
Table 6: Global: Antibody Drug Conjugates Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 7: Global: Antibody Drug Conjugates Market: Competitive Structure
Table 8: Global: Antibody Drug Conjugates Market: Key Players

02-2729-4219

+886-2-2729-4219